Screener
Haemonetics HAE Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
As of June 27, 2026, the Company had $31.0 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 70% of this amount as revenue within the next twelve months and the remaining balance thereafter.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's deferred revenue?
- Haemonetics (HAE) reported deferred revenue of $31M in Q2 2026.
- How has Haemonetics's deferred revenue changed year-over-year?
- Haemonetics's deferred revenue decreased by 13.9% year-over-year, from $36M to $31M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Haemonetics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude